Stockreport

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Astria Therapeutics, Inc.  (ATXS) 
PDF -- ALPHA-STAR Trial of STAR-0215 Initial Proof-of-Concept Data in HAE Patients Expected Q1 2024 ---- STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of [Read more]